{
    "clinical_study": {
        "@rank": "30360", 
        "brief_summary": {
            "textblock": "This is a dose-escalation study to determine the maximum tolerated dose and toxic effects of\n      clofarabine in patients with chronic lymphocytic leukemia and other acute leukemias.\n      Clofarabine is a synthesized hybrid nucleoside analog, which is believed to possess the\n      better qualities of fludarabine and chlorodeoxyadenosine, the 2 most active agents against\n      lymphoproliferative disorders. Thus, it is hoped that this drug will be more active and less\n      toxic than similar drugs."
        }, 
        "brief_title": "Clofarabine in Chronic Lymphocytic Leukemia", 
        "completion_date": "March 2001", 
        "condition": [
            "Hematologic Neoplasms", 
            "Lymphoproliferative Disorders", 
            "Leukemia", 
            "Leukemia, Lymphocytic, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoproliferative Disorders", 
                "Hematologic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The first group of patients will be treated at the starting dose level of 2 mg/m2 over 1\n      hour daily for 5 days. Dosage escalation will be permitted in individual patients if no\n      toxicity occurred during the preceding course. Subsequent dose escalations will be by 50%\n      until Grade 2 toxicity, then by 35% until the maximum tolerated dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Diagnosis of chronic lymphocytic leukemia\n\n          -  Diagnosis of other acute leukemia\n\n          -  At least 2 weeks since prior chemotherapy, immunotherapy, and/or radiotherapy\n\n          -  Recovered from toxic effects of prior therapy\n\n          -  Bilirubin no greater than 2 mg/dL\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n        Exclusion criteria:\n\n          -  Candidate for treatment of higher efficacy or priority\n\n          -  Pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "January 4, 2002", 
        "id_info": {
            "nct_id": "NCT00028418", 
            "org_study_id": "FD-R-1972-01", 
            "secondary_id": "DM93-036; FD-R-001972-01"
        }, 
        "intervention": {
            "intervention_name": "Clofarabine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Clofarabine", 
                "Antineoplastic Agents"
            ]
        }, 
        "keyword": [
            "Acute Leukemia", 
            "Chronic Lymphocytic Leukemia", 
            "Antineoplastic Agents", 
            "Nucleosides", 
            "Dose-Response Relationship, Drug", 
            "Cladribine", 
            "Fludarabine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "University of Texas M. D. Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I Study of CL-F-ARA-A in Solid and Hematologic Malignancies", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Hagop M. Kantarjian, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00028418"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "February 1999", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2001"
    }, 
    "geocoordinates": {
        "University of Texas M. D. Anderson Cancer Center": "29.76 -95.369"
    }
}